Joe Payne, the CEO of Arcturus Therapeutics, is back to talk about exciting progress on their messenger RNA Covid-19 vaccine and answer questions about testing for antibodies versus T-cell immunity, potential longevity and timing of the vaccine, and what countries are signing up for the potential Arcturus solution. He also talks about what we might expect after the pandemic slows and how Covid-19 might be similar to or differ from the seasonal influenza, and how public education will be key. Another must-listen episode to stay current.The Arcturus website:https://arcturusrx.com/The UCSF Grand Rounds talk we mention:https://www.youtube.com/watch?v=kNADw5io9MsThe first episode with Joe from April 2020:https://www.podomatic.com/podcasts/deardiscreetguide/episodes/2020-04-26T05_00_00-07_00Thoughts? Comments? Potshots? Contact the show at:https://www.discreetguide.com/Follow or like us on podomatic.com (it raises our visibility :)https://www.podomatic.com/podcasts/deardiscreetguideSupport us on Patreon:https://www.patreon.com/discreetguideFollow the host on Twitter:@DiscreetGuideThe host on LinkedIn:https://www.linkedin.com/in/jenniferkcrittenden/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related